(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 19 April 2007 (19.04.2007)

PCT

(10) International Publication Number WO 2007/043923 A1

(51) International Patent Classification: *A61N 1/365* (2006.01) *A61B 5/053* (2006.01)

(21) International Application Number:

PCT/SE2005/001530

(22) International Filing Date: 11 October 2005 (11.10.2005)

(25) Filing Language:

Englis

(26) Publication Language:

English

(71) Applicant (for all designated States except US): ST. JUDE MEDICAL AB [SE/SE]; S-175 84 Järfälla (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): OLSON, Allan [SE/SE]; Sörgårdsvägen 80, S-163 52 Spånga (SE). WONG, Louis [AU/US]; 1070 Lois Avenue, Sunnyvale, CA 94087 (US).

(74) Common Representative: ST. JUDE MEDICAL AB; S-175 84 Järfälla (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND IMPLANTABLE MEDICAL DEVICE FOR MEASURING AN ELECTRICAL BIO-IMPEDANCE OF A PATIENT



(57) Abstract: The present invention relates to a method for measuring an electrical bio-impedance of a patient with an implanted medical device comprising at least one electrode configuration, wherein at least one asymmetric multiphasic impedance measurement waveform is generated in order to generate the impedance measurement signal, the at least one asymmetric multiphasic impedance measurement waveform having a DC component being substantially equal to zero. Furthermore, the invention relates to a medical device for measuring an electrical bio-impedance of a patient and a computer readable medium comprising instructions for bringing a computer to perform the inventive method.



METHOD AND IMPLANTABLE MEDICAL DEVICE FOR MEASURING AN ELECTRICAL BIO-IMPEDANCE OF A PATIENT

TECHNICAL FIELD

The present invention generally relates to implantable medical devices, such as cardiac pacemakers and implantable cardioverter/defibrillators, and in particular to an improved method and medical device for measuring electrical bio-impedance signals.

BACKGROUND OF THE INVENTION

- 10 Electrical bio-impedance signals has been found to be an useful tool in implantable medical devices, such as cardiac pacemakers. For example, electrical bio-impedance signals can be used to determine the amount of air being inhaled by a patient to assess the patient's need for cardiac output in order to provide a proper pacing pulse rate to the patient since measuring the impedance of the chest cavity has been found to provide a good indication of the amount of air 15 being inhaled by a patient. One example of this is described in US 5,197, 467. Furthermore, electrical bio-impedance has been found to be an effective measure for identifying changes of many different conditions in the body of a patient, such as incipient pulmonary edema and the progression of pulmonary edema due to CHF. For example, the accumulation of fluids in the lung-region associated with pulmonary edema affects the thoracic impedance, since the 20 resistivity of the lung changes in accordance with a change of the ratio of fluid to air. As indicated in US 5,957,861, it is possible to detect pulmonary edema at an early stage by means of transthoracic impedance measured by an implanted device such as a pacemaker.
- In addition to the thoracic impedance, the cardiogenic impedance, which is defined as the impedance or resistance variation that origins from cardiac contractions measured by electrodes inside or on the surface of the body, can be used for identifying changes different conditions in the heart of a patient. The cardiogenic impedance variation correlates to the volume changes of the heart chambers, which can be used as an indication of the dynamic blood filling. Hence, changes of parameters such as left ventricular ejection time (LVET) can be detected by monitoring or detecting changes of the cardiogenic impedance, see, for example US Pat 6,511,438.

Accordingly, a reliable and accurate method for measuring or detecting electrical bioimpedances, such as the intra thoracic impedance or the cardiogenic impedance, i.e. the cardiac

30

component of an impedance signal measured over the heart, in an implantable medical device would be of a great value.

Conventionally, when generating multi-phasic impedance measurement current pulses, a positive and a negative current of equal amplitude and width has been used in order to only 5 make use of fully balanced signals, i.e. integrating over the complete current pulse should ideally give a zero area. It is believed that a multi-phasic, for example, a biphasic excitation pulse offers the advantages over a monophasic pulse that the peak amplitude of the excitation pulse is minimized given the overall energy content of the pulse, electrode polarization is 10 cancelled, and DC current is balanced to avoid long-term lead metal-ion oxidation, see, for example, U.S. 6,269,264, and U.S. 6,104,949. However, since the pulse generator of a conventional implantable medical device, such as a pacemaker, typically operates around 0.5-0.9 V with the case or housing of the device as the negative supply, i.e. 0 V, and the battery (about -2.8 V) as the positive supply, the negative voltage headroom is significantly lower than 15 the positive headroom. The current pulse amplitude is hence limited by the negative voltage headroom and the complete potential operating range of the pulse generator is not utilized. This may, in turn, entail to an impaired signal-to-noise ratio of the measured impedance signal.

Accordingly, there is a need of an improved method and medical device that are able to obtain reliable and accurate electrical bio-impedance signals.

BRIEF DESCRIPTION OF THE INVENTION

Thus, an object of the present invention is to provide an improved method and medical device that are able to obtain more reliable and accurate electrical bio-impedance signals.

This and other objects are achieved according to the present invention by providing a method, medical devices, and a computer readable medium having the features defined in the independent claim. Preferable embodiments of the invention are characterised by the dependent claims.

In the context of this application, the term "impedance" refers to the DC component of the impedance. The measured impedance consists of a DC component and an AC component, where the DC component is the baseline around which the AC component fluctuates. The DC component reflects the amount of tissue and fluids that are located between the measuring

15

20

25

30

35

points that the impedance is measured in-between and the AC components reflects how respiration and cardiac activity influence the impedance signal.

For the purpose of clarity, the term "intra thoracic impedance" refers to an impedance measurement over the thorax by using an implantable medical device, i.e. an impedance measurement where the impedance measurement vector spans over the thorax.

Moreover, in order to clarify, the term "cardiogenic impedance" is defined as the impedance or resistance variation that origins from cardiac contractions or, in other words, the cardiac component of the impedance measured between electrodes within the heart.

According to an aspect of the present invention, there is provided a method for measuring an electrical bio-impedance of a patient with an implanted medical device comprising at least one electrode configuration, comprising the steps of: initiating an electrical bio-impedance measurement session, wherein at least one impedance measurement signal is generated; applying the generated at least one impedance measurement signal to the patient using the at least one electrode configuration; measuring at least one resulting impedance signal produced by the applied at least one impedance measurement signal; and determining at least one impedance value using the measured impedance signal. The method is characterized by the step of generating at least one asymmetric multiphasic impedance measurement waveform in order to generate the impedance measurement signal, wherein the at least one asymmetric multiphasic impedance measurement waveform has a DC component being substantially equal to zero.

According to a second aspect of the present invention, there is provided an implantable medical device for measuring an electrical bio-impedance of a patient with an implanted medical device comprising at least one electrode configuration, comprising: a control circuit; an impedance circuit connected to the control circuit, which control circuit is adapted to influence the impedance circuit to initiate an electrical bio-impedance measurement session, wherein at least one impedance measurement signal is generated and applied to the patient using the at least one electrode configuration; a voltage signal measurement circuit connected to the control circuit and adapted to measure at least one resulting impedance signal produced by the applied at least one impedance measurement signal; and wherein the control circuit being adapted to determine at least one impedance value using the measured impedance signal. The medical device is characterized in that the control circuit is adapted to influence the impedance circuit to generate at least one asymmetric multiphasic impedance measurement waveform in order to generate the

15

20

25

30

impedance measurement signal, wherein the at least one asymmetric multiphasic impedance measurement waveform has a DC component being substantially equal to zero.

According to a third aspect of the present invention, there is provided a computer readable medium comprising instructions for bringing a computer to perform a method according to the first aspect.

Thus, the invention is based on the idea of using asymmetrical current waveforms thereby making it possible to utilize, in principle, substantially the complete potential positive voltage headroom as the same time as the waveforms has a zero DC component. In other words, by generating pulses being asymmetric in terms of pulse magnitude or amplitude and/or pulse width about the operating voltage of the current pulse generator, it is possible to make use of the positive voltage headroom and still obtain a fully balanced impedance measurement signal. The asymmetric pulses thus enables a more efficient usage of the operating range of the current pulse generator.

This solution provides several advantages over the existing solutions. One advantage is that an improved signal-to-noise ratio can be obtained in comparison to the known technique due to the fact that the total energy content of the impedance measurement signal can be increased.

Another advantage is that the impedance measurement signal according to the present invention does not create significant interference in the low frequency range in which, for example, typical ECG machines are sensitive since the generated signal has a zero DC component. Hence, interference with an external device, such as an ECG machine, can be minimized.

In one embodiment, the at least one asymmetric multiphasic impedance measurement waveform comprises a number of pulses having predetermined asymmetrically distributed pulse amplitudes and pulse widths about an operating voltage of the current pulse generator of the medical device.

In accordance with one embodiment of the present invention, at least one null period having a predetermined length is generated, wherein the null period is intermediate to two successive pulses.

WO 2007/043923 PCT/SE2005/001530 5

According to another embodiment, at least one asymmetric pentaphasic impedance measurement waveform is generated by: generating a first pulse of a predetermined first amplitude and a predetermined first pulse width; generating a first null period immediately following the first period and having a predetermined period length; generating a second pulse immediately following the first null period, the second pulse being of a reversed polarity to the first pulse and having a predetermined second amplitude and a predetermined second pulse width; generating a second null period immediately following the second pulse and having the predetermined period length; and generating a third pulse immediately following the second null period, the third pulse being of a reversed polarity to the second pulse and having the predetermined first amplitude and a predetermined first pulse width. This waveform has been found to be particularly suitable in respect of, for example, usage of the positive voltage headroom and thus enables a more efficient usage of the operating range of the current pulse generator.

In a further embodiment, at least one asymmetric triphasic impedance measurement waveform is generated by: generating a first pulse of a predetermined first amplitude and a predetermined first pulse width; generating a second pulse immediately following the first pulse, the second pulse being of a reversed polarity to the first pulse and having a predetermined second amplitude and a predetermined second pulse width; and generating a third pulse immediately following the second pulse, the third pulse being of a reversed polarity to the second pulse and having the predetermined first amplitude and a predetermined first pulse width. This waveform has also been found to be suitable in respect of, for example, usage of the positive voltage headroom and thus enables a more efficient usage of the operating range of the current pulse generator.

25

30

5

10

The features that characterize the invention, both as to organization and to method of operation, together with further objects and advantages thereof, will be better understood from the following description used in conjunction with the accompanying drawings. It is to be expressly understood that the drawings is for the purpose of illustration and description and is not intended as a definition of the limits of the invention. These and other objects attained, and advantages offered, by the present invention will become more fully apparent as the description that now follows is read in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

In the following detailed description, reference will be made to the accompanying drawings, of which:

- Fig. 1 is schematic diagram showing a medical device implanted in a patient in which device the present invention can be implemented.
 - Fig. 2 is block diagram of the primary functional components of an embodiment of the present invention.
- Fig. 3a is an illustrative pentaphasic impedance measurement waveform in accordance with the present invention;
- Fig. 3b illustrates the integrated area of the pentaphasic impedance measurement waveform shown in Fig. 3a;
 - Fig. 4a is an illustrative triphasic impedance measurement waveform in accordance with the present invention; and
- Fig. 4b illustrates the integrated area of the pentaphasic impedance measurement waveform shown in Fig. 4a.

DETAILED DESCRIPTION OF THE INVENTION

With reference to Fig. 1 there is shown a schematic diagram of a medical device implanted in a patient in which device the present invention can be implemented. As seen, this embodiment of the present invention is shown in the context of a pacemaker 2 implanted in a patient (not shown). The pacemaker 2 comprises a housing being hermetically sealed and biological inert. Normally, the housing is conductive and may, thus, serve as an electrode. One or more pacemaker leads, where only two are shown in Fig. 1 namely a ventricular lead 6a and an atrial lead 6b, are electrically coupled to the pacemaker 2 in a conventional manner. The leads 6a, 6b extend into the heart 8 via a vein 10 of the patient. One or more conductive electrodes for receiving electrical cardiac signals and/or for delivering electrical pacing to the heart 8 are arranged near the distal ends of the leads 6a, 6b. As the skilled man in the art realizes, the leads 6a, 6b may be implanted with its distal end located in either the atrium or ventricle of the heart

8. Impedance measurements signals may be applied suing an electrode on one of the cardiac leads 6a, 6b and the housing or case, i.e. the external housing of the pacemaker 2. Unipolar leads have a single electrode and bipolar leads have tip an ring electrodes. If bipolar leads are being used, the impedance measurement signals may be applied to the body of the patient between a ring electrode and the housing of the pacemaker 2 and the resulting voltage signal can be measured between the tip electrode and the housing of the pacemaker 2. There are in fact a number of possible impedance configurations, i.e. ways of injecting current between two electrodes in the pacemaker and then to measure the voltage the current provokes between the electrodes. For example, impedance configurations can be uni-polar, bi-polar, tri-polar or quadro-polar. The configuration denominated as bi-polar means, in practice, a configuration where the current and the voltage is sent out and measured between the same two electrodes. When one of the electrodes used in a bi-polar measurement is the housing or the case, the configuration is called uni-polar. For example, in Fig. 1, between the housing of the pacemaker 2 and a right ventricular electrode arranged at the distal end of lead 6a. A tri-polar configuration uses three electrodes, i.e. the current injection and the voltage measurement share one electrode. As an example, the current can be sent out from the housing or the case of the medical device to a RV-tip and the voltage is measured between the case and RV-ring. In quadro-polar measurements, the current is sent out between electrodes and the voltage is measured between two entirely different electrodes, i.e. in this case there are four electrodes involved.

PCT/SE2005/001530

20

25

30

35

15

5

10

With reference now to Fig. 2, the configuration including the primary components of an embodiment of the present invention will be described. The illustrated embodiment comprises an implantable medical device 20, such as the pacemaker shown in Fig. 1, and leads 26a and 26b, of the same type as the leads 6a and 6b shown in Fig. 1. The leads 26a, 26b may be unipolar or bipolar, and may include any of the passive or active fixation means known in the art for fixation of the lead to the cardiac tissue. As an example, the lead distal tip (not shown) may include a tined tip or a fixation helix. The leads 26a, 26b comprises one or more electrodes (as described with reference to fig. 1), such a tip electrode or a ring electrode, arranged to, inter alia, transmit pacing pulses for causing depolarization of cardiac tissue adjacent to the electrode(-s) generated by a pace pulse generator 25 included in an output circuit 23 under influence of a control circuit 27, which preferably is micro-processor based. The control circuit 27 controls the operation of the pacemaker 20 based on the execution of instructions stored in a memory or storage means 31, which may include a random access memory (RAM) and/or a non-volatile memory such as a read-only memory (ROM). Detected signals from the patients heart are processed in an input circuit 33 connected to the control circuit 27. The pacemaker 20

10

15

20

25

30

35

may transmit data signals from within the patient using a telemetry circuit 35. Data signals transmitted by the telemetry circuit 35 are picked up by a conventional programmer (not shown). Various programmable parameters of the pacemaker 20 can be adjusted by a physician by sending control signals to the pacemaker 20 via the telemetry circuit 35 using the programmer.

The input circuit 33 monitors the cardiac signals of the heart 8 (see Fig. 1). Thereby, the presence of cardiac events such as, for example, P-waves or R-waves can be established. The control circuit 27 is adapted to analyze the cardiac signals monitored by the input circuit 33. Moreover, the control circuit 27 is adapted to determine whether the output circuit should apply pacing pulses to the heart 8 (see fig. 1) and to determine pace pulse parameters such as output voltage and pulse duration.

Furthermore, the output circuit 23 comprises an impedance circuit 29. The impedance circuit 29 is arranged to apply excitation current pulses between a first electrode arranged to positioned within a heart of the patient and second electrode in an embodiment where the intra thoracic impedance is measured. The input circuit 33 is adapted to measure the resulting signal across the heart. The control circuit 27 is adapted to analyze the impedance measurement signal generated by the impedance circuit 29 and the resulting signal measured by the input circuit 33 in order to determine the impedance of the body of the patient, for example, the intra thoracic impedance. Typically, the impedance measurement signal is a current of known magnitude and the resulting signal measured across the body is a voltage signal. Alternatively, the impedance measurement signal applied to the body may be a voltage of known magnitude. If the voltage of the applied impedance measurement signal is known, the resulting magnitude of the current of the signal through the body can be measured to determine the impedance. Analyzing the impedance measurement signal and the resulting signal to determine the impedance typically involves processing these signals to determine their relative magnitudes. For example, in the absence of significant capacitive or inductive effects, the impedance of the patient's body may be calculated using Ohm's law (i.e. body impedance equals measured voltage divided by applied current).

The impedance measurement signal is preferably an AC (alternating current) impedance measurement current signal with a magnitude of $10~\mu A$ to $1000~\mu A$ generated by a current pulse generator 37 of the impedance circuit 29. Preferably, each pulses of the generated waveform has a length of about 10 - $80~\mu s$ Applying the impedance measurement signal over the heart 8 (see

25

30

35

fig. 1) via any one of the leads 26a and 26 b gives rise to an impedance voltage signal, which is measured using a voltage signal measurement circuit 39 of the input circuit 33. The voltage signal measurement circuit 39 may comprise an AC amplifier (not shown) for amplifying the measured voltage signal and a demodulator (not shown) adapted to rectify the received signal and to provide a DC (direct current) output voltage signal. The resulting output DC voltage signal is digitized by an analog-to-digital converter (not shown) and communicated to the control circuit 27.

As described above, conventional impedance measurement signals are constituted of a series of 10 square waves, where a positive and a negative current of equal amplitude and pulse width is used in order to only make use of fully balanced signals. In other words, integrating over the complete current pulse should ideally give a zero area. However, since the pulse generator of a conventional implantable medical device, such as a pacemaker, typically operates around 0.5-0.9 V with the case or housing of the device as the negative supply, i.e. 0 V, and the battery 15 (about -2.8 V) as the positive supply, the negative voltage headroom is significantly lower than the positive headroom. In fact, the negative voltage headroom is at minimum about 0.5 V compared to the positive voltage headroom of about 2.8 - 0.9 = 1.9 V. In contrast, in accordance to the present invention, the control circuit 27 is adapted to influence the current pulse generator 37 (Fig. 2) of the impedance circuit 29 to generate asymmetric mutliphasic 20 waveforms, which, among other things, exhibit an improved signal-to-noise ratio and a reduced content of low frequency components in comparison with prior art.

According to an preferred embodiment of the present invention, at least one pulse having a voltage amplitude being higher that the operating voltage and having a predetermined pulse width, at least one pulse having a voltage amplitude being lower than the operating voltage and having a predetermined pulse width are generated. In this embodiment, the absolute value of the amplitude being higher that the operating voltage is not equal to an absolute value of the amplitude being lower than the operating voltage and/or the pulse width of the pulse having an amplitude being higher than the operating voltage is not equal to the pulse width of the pulse having an amplitude being lower than the operating voltage.

With reference now to Fig. 3a, an illustrative asymmetric multiphasic waveform according to an embodiment of the present invention is shown. The first portion of the waveform 40 contains a pulse 42 with a negative polarity having a pulse amplitude of A1 and a pulse width of T1. A null period 44, having a length of T2, follows immediately after the first pulse 42. Immediately

thereafter, a positive pulse 46 having a pulse amplitude A2 and a pulse width T3 will follow. In a preferred embodiment, an absolute value of the amplitude A2 of the positive pulse 46 is about four times higher than an absolute value of the amplitude A1 of the negative pulse 42. Moreover, the length T3 of the positive pulse 46 is about half the length T1 of the negative pulse 42. A second null period 48 having a length of T4 follows immediately after the positive pulse 46. Preferably, the length of the second null period T4 and the length of the first null period T2 is equal. Finally, a pulse 50 with a negative polarity having a pulse amplitude A3 and a pulse width of T5 follows. Preferably, the pulse amplitude A3 and the pulse width T5 of the final pulse 50 of the waveform 40 are equal to the pulse amplitude A1 and the pulse width T1 of the first pulse 42 of the waveform 40, respectively. Suitable values for the lengths T1-T5 and amplitudes A1-A3 are about $10-80~\mu s$ and $10-1000~\mu A$ respectively. Another waveform that may be generated by the current pulse generator 37 is the triphasic waveform 60 illustrated in Fig. 4a. The waveform 60 has a negative pulse 62 of a pulse amplitude A7 and pulse width T6. A positive pulse 64 having a pulse amplitude of A8 and a pulse width of T7 follows immediately after the first pulse 62 and a second negative pulse 66

20

25

5

10

15

As can be seen in Figs. 3b and 4b, the pentaphasic waveform illustrated in Fig. 3a and the triphasic waveform illustrated in Fig. 4a have DC components being substantially zero, meaning a zero value after integration. Thus, at least one asymmetric multiphasic impedance measurement waveform comprising a number of pulses having predetermined asymmetrically distributed pulse amplitudes and pulse widths about an operating voltage of a pulse generator of the medical device is generated

having a pulse amplitude A9 and a pulse width T8 follows after the positive pulse 64.

about $10 - 80 \mu s$ and $10 - 1000 \mu A$ respectively.

Preferably, the amplitude A7 of the first negative pulse 62 is equal to the amplitude A9 of the second negative pulse 66. Suitable values for the lengths T7-T9 and amplitudes A7-A9 are

Although an exemplary embodiment of the present invention has been shown and described, it will be apparent to those having ordinary skill in the art that a number of changes,

modifications, or alterations to the inventions as described herein may be made. Thus, it is to be understood that the above description of the invention and the accompanying drawings is to be regarded as a non-limiting example thereof and that the scope of protection is defined by the appended patent claims.

CLAIMS

5

10

15

20

35

1. A method for measuring an electrical bio-impedance of a patient with an implanted medical device (20) comprising at least one electrode configuration, comprising the steps of:

initiating an electrical bio-impedance measurement session, wherein at least one impedance measurement signal is generated;

applying said generated at least one impedance measurement signal to said patient using said at least one electrode configuration;

measuring at least one resulting impedance signal produced by said applied at least one impedance measurement signal; and

determining at least one impedance value using said measured impedance signal; characterized by the step of:

generating at least one asymmetric multiphasic impedance measurement waveform in order to generate said impedance measurement signal, said at least one asymmetric multiphasic impedance measurement waveform having a DC component being substantially equal to zero.

- 2. The method according to claim 1, wherein the step of generating comprises the step of generating at least one asymmetric multiphasic impedance measurement waveform comprising a number of pulses having predetermined asymmetrically distributed pulse amplitudes and pulse widths about an operating voltage of a pulse generator (37) of said medical device.
- 3. The method according to claim 2, wherein the step of step of generating at least one asymmetric multiphasic impedance measurement waveform comprises the step of: generating at least one null period having a predetermined length, said null period being intermediate to two successive pulses.
- 4. The method according to any one of the preceding claims 1-3, wherein the step of generating at least one asymmetric multiphasic impedance measurement waveform comprises the step of generating at least one asymmetric pentaphasic impedance measurement waveform (40), the step of generating a asymmetric pentaphasic impedance measurement waveform comprising the steps of:

generating a first pulse (42) of a predetermined first amplitude (A1) and a

predetermined first pulse width (T1);

generating a first null period (44) immediately following the first period (42) and having a predetermined period length (T2);

generating a second pulse (46) immediately following the first null period (44), the second pulse (46) being of a reversed polarity to the first pulse (42) and having a predetermined second amplitude (A2) and a predetermined second pulse width (T3);

generating a second null period (48) immediately following the second pulse (46) and having the predetermined period length (T4); and

generating a third pulse (50) immediately following the second null period (48), the third pulse (50) being of a reversed polarity to the second pulse (46) and having the predetermined first amplitude (A3) and a predetermined first pulse width (T5).

5. The method according to claim 1 or 2, wherein the steps of generating at least one asymmetric multiphasic impedance measurement waveform comprises the step of generating at least one asymmetric triphasic impedance measurement waveform (60), the step of generating a asymmetric pentaphasic impedance measurement waveform comprising the steps of:

generating a first pulse (62) of a predetermined first amplitude (A7) and a predetermined first pulse width (T6);

generating a second pulse (64) immediately following the first pulse (62), the second pulse being of a reversed polarity to the first pulse (62) and having a predetermined second amplitude (A8) and a predetermined second pulse width (T7); and

generating a third pulse (66) immediately following the second pulse (64), the third pulse (66) being of a reversed polarity to the second pulse (64) and having the predetermined first amplitude (A9) and a predetermined first pulse width (T8).

- 6. The method according to claim 1, wherein the step of determining at least one impedance value comprises the step of analyzing the magnitudes of said at least one resulting impedance signal and said generated at least one impedance measurement signal.
- 7. An implantable medical device (20) for measuring an electrical bio-impedance of a patient with an implanted medical device comprising at least one electrode configuration, comprising:

10

5

15

20

25

30

35

a control circuit (27);

an impedance circuit (29) connected to said control circuit (27), said control circuit being adapted to influence said impedance circuit (29) to initiate an electrical bio-impedance measurement session, wherein at least one impedance measurement signal is generated by a current pulse generator (37) of said impedance circuit (29) and applied to said patient using said at least one electrode configuration;

a voltage signal measurement circuit (39) connected to said control circuit (27) and adapted to measure at least one resulting impedance signal produced by said applied at least one impedance measurement signal; and

wherein said control circuit (27) is adapted to determine at least one impedance value using said measured impedance signal; characterized in that:

said control circuit (27) is adapted to influence said current pulse generator (37) of said impedance circuit (29) to generate at least one asymmetric multiphasic impedance measurement waveform in order to generate said impedance measurement signal, said at least one asymmetric multiphasic impedance measurement waveform having a DC component being substantially equal to zero.

- 8. The device according to claim 7, wherein said control circuit (27) is adapted to influence said current pulse generator (37) of said impedance circuit (29) to generate at least one asymmetric multiphasic impedance measurement waveform comprising a number of pulses having predetermined asymmetrically distributed pulse amplitudes and pulse widths about an operating voltage of said current pulse generator (37) of said medical device (20).
- 9. The device according to claim 9, wherein said control circuit (27) is adapted to influence said current pulse generator (37) of said impedance circuit (29) to generate at least one null period having a predetermined length, said null period being intermediate to two successive pulses.
- 30 10. The device according to any one of the preceding claims 7-9, wherein said control circuit (27) is adapted to influence said current pulse generator (37) of said impedance circuit (29) to generate at least one asymmetric pentaphasic impedance measurement waveform by

generating a first pulse (42) of a predetermined first amplitude (A1) and a predetermined first pulse width (T1);

10

5

15

20

35

generating a first null period (44) immediately following the first period (42) and having a predetermined period length (T2);

generating a second pulse (46) immediately following the first null period (44), the second pulse (46) being of a reversed polarity to the first pulse (42) and having a predetermined second amplitude (A2) and a predetermined second pulse width (T3);

generating a second null period (48) immediately following the second pulse (46) and having the predetermined period length (T4); and

generating a third pulse (50) immediately following the second null period (48), the third pulse (50) being of a reversed polarity to the second pulse (46) and having the predetermined first amplitude (A3) and a predetermined first pulse width (T5).

11. The device according to claim 7 or 8, wherein said control circuit (27) is adapted to influence said current pulse generator (37) of said impedance circuit (29) to generate at least one asymmetric triphasic impedance measurement waveform by:

generating a first pulse (62) of a predetermined first amplitude (A7) and a predetermined first pulse width (T6);

generating a second pulse (64) immediately following the first pulse (62), the second pulse being of a reversed polarity to the first pulse (62) and having a predetermined second amplitude (A8) and a predetermined second pulse width (T7); and

generating a third pulse (66) immediately following the second pulse (64), the third pulse (66) being of a reversed polarity to the second pulse (64) and having the predetermined first amplitude (A9) and a predetermined first pulse width (T8).

- 12. The method according to claim 7, wherein said control circuit (27) is adapted to analyze the magnitudes of said at least one resulting impedance signal and said generated at least one impedance measurement signal.
- 13. Computer readable medium comprising instructions for bringing a computer to perform a method according to any one of the preceding claims 1-6.

15

5

25





Fig. 1






Fig. 3




Fig. 4

International application No.

PCT/SE2005/001530

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61N, A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
US 6044294 A (MORTAZAVI, S. ET AL), 28 March 2000 (28.03.2000), column 2, line 9 - line 32; column 5, line 20 - line 44, figure 5, claim 1	1-13
US 6269264 B1 (WEYANT, R.R. ET AL), 31 July 2001 (31.07.2001), column 2, line 10 - column 10, line 32; column 5, line 21 - line 44, figure 5, claim 1	1-13
	
US 5713935 A (PRUTCHI, D. ET AL), 3 February 1998 (03.02.1998), column 2, line 41 - column 3, line 12; column 4, line 62 - line 64; column 6, line 32 - line 41, figures 5,6, claim 1	1-13
	
	(28.03.2000), column 2, line 9 - line 32; column 5, line 20 - line 44, figure 5, claim 1 US 6269264 B1 (WEYANT, R.R. ET AL), 31 July 2001 (31.07.2001), column 2, line 10 - column 10, line 32; column 5, line 21 - line 44, figure 5, claim 1 US 5713935 A (PRUTCHI, D. ET AL), 3 February 1998 (03.02.1998), column 2, line 41 - column 3, line 12; column 4, line 62 - line 64; column 6,

Х	Further documents are listed in the continuation of Box	. C.	X See patent family annex.		
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand		
	to be of particular relevance		the principle or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive		
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		step when the document is taken alone		
	special reason (as specified)	"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is		
"O"	document referring to an oral disclosure, use, exhibition or other means		combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report			
15 May 2006			1 6 -05- 2006		
Name and mailing address of the ISA/		Autho	orized officer		
Swe	edish Patent Office		•		
Box 5055, S-102 42 STOCKHOLM		Gordana Nincovic /OGU			
Fac	simile No. +46 8 666 02 86	Telep	hone No. + 46 8 782 25 00		
	DOMITO 4 1010 (

International application No.

PCT/SE2005/001530

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 20020040192 A1 (PRUTCHI, D.), 4 April 2002 (04.04.2002), paragraphs 0036-0038, figure 2, claim 1, abstract	1-13
A	US 6076015 A (HARTLEY, J.W. ET AL), 13 June 2000 (13.06.2000), figure 3, claim 1, abstract	1-13
A	US 5534018 A (WAHLSTRAND, J.D. ET AL), 9 July 1996 (09.07.1996), column 5, line 3 - line 29, figure 2, claim 1, abstract	1-13
A	US 6208898 B1 (GLINER, B.E. ET AL), 27 March 2001 (27.03.2001), abstract	1-13
A	MATULA, M.H. et al: "Biphasic waveforms for ventricular defibrillation: optimization of total pulse and second phase durations" PACING AND CLINICAL ELECTROPHYSIOLOGY, September 1997, vol.20, nr.9, pt.1, pg. 2154-2162, see abstract	1-13
E	US 7024241 B1 (BORNZIN, G.A. ET AL), 4 April 2006 (04.04.2006), paragraphs 0075-0078, figure 6, abstract	1-13

International application No. PCT/SE2005/001530

International patent classification (IPC)

A61N 1/365 (2006.01)

A61B 5/053 (2006.01)

Download your patent documents at www.prv.se

Cited patent documents can be downloaded at www.prv.se by following the links e-tjänster/anförda dokument. Use the application number as username. The password is AORBDOVWPK.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

International application No. PCT/SE2005/001530

Box No. I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This inter	national search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: 1-6 because they relate to subject matter not required to be searched by this Authority, namely:
aniı metl exe	im 1-6 relate to a method of treatment of the human or mal body by surgery or by therapy, as well as diagnostic hods /Rule 39.1(iv). Nevertheless, a search has been cuted for these claims. The search has been based on the eged effects of the device.
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No.	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.

Information on patent family members

04/03/2006

International application No. PCT/SE2005/001530

US US US	6044294 6269264 5713935	A B1	28/03/2000 31/07/2001	US	6269264	В	31/07/200
			31/07/2001	lic			
US	5713935			US	6044294	A	28/03/200
		A	03/02/1998	CA		A	26/02/199
				EP WO	0929345 9807467	A A	21/07/199 26/02/199
US 20	020040192	A1	04/04/2002	US		В	11/11/200
				US		В	09/04/200
				CA	2320277		12/08/199
				EP	1052934	A	22/11/200
				JP	2002501805	Ţ	22/01/200
				US.	6022322		08/02/200
				WO	9939636		12/08/19
US	6076015	Α	13/06/2000	AT	300332	T	15/08/200
				CA	2322174		02/09/19
				DE	69926347		00/00/00
				EP	1061998		27/12/20
				US	6161042		12/12/20
				US	6463326	_	08/10/20
				US		A	05/06/20
				WO	9943385	A 	02/09/19
US	5534018	A	09/07/1996	AU	4406696	A	19/06/19
				WO	9616694	Α	06/06/19
US	6208898	B1	27/03/2001	DE	10012503	Α	19/10/20
				GB	0007226	D	00/00/00
			ā	GB	2348139		27/09/20
				JP	2000288100	A 	17/10/20
US	7024241	B1	04/04/2006	NON	E		